about
sameAs
Validity and reliability of the Structured Clinical Interview for Depersonalization-Derealization Spectrum (SCI-DER)Epilepsy, Antiepileptic Drugs, and Aggression: An Evidence-Based ReviewUncovering the neurobehavioural comorbidities of epilepsy over the lifespanProfile of once-daily zonisamide as monotherapy for treatment of partial seizures in adultsTreatment of anxiety disorders in epilepsy: an evidence-based approachPsychosocial aspects of epilepsy: a wider approachThird International Congress on Epilepsy, Brain and Mind: Part 1Using anxiolytics in epilepsy: neurobiological, neuropharmacological and clinical aspects.Complex pattern of convulsive syncope in glossopharyngeal neuralgia: video/EEG report and short review.Epilepsy in Dante's poetry.Anxiety symptoms in epilepsy: salient issues for future research.Depression and epilepsy: epidemiologic and neurobiologic perspectives that may explain their high comorbid occurrence.Suicide risk in people with epilepsy taking antiepileptic drugs.Negative effects of antiepileptic drugs on mood in patients with epilepsy.Ictal and peri-ictal psychopathology.The role of anticonvulsant drugs in anxiety disorders: a critical review of the evidence.The global burden and stigma of epilepsy.Pharmacokinetic Interactions between Antiepileptic and Antidepressant Drugs.The factor structure of lifetime depressive spectrum in patients with unipolar depression.The structure of lifetime manic-hypomanic spectrum.Use of psychotropic drugs in patients with epilepsy: interactions and seizure risk.Consciousness, epilepsy, and emotional qualia.The neurobiology and clinical significance of depersonalization in mood and anxiety disorders: a critical reappraisal.Measuring the level and content of consciousness during epileptic seizures: the Ictal Consciousness Inventory.Epilepsy, cognition, and neuropsychiatry (Epilepsy, Brain, and Mind, part 2)Antiepileptic drugs and psychopathology of epilepsy: an update.Epilepsy and bipolar disorders.Suicidality in epilepsy and possible effects of antiepileptic drugs.GABAergic drugs in the treatment of epilepsy: modern or outmoded?Recent and future antiepileptic drugs and their impact on cognition: what can we expect?Antiepileptic drugs and suicidality: an expert consensus statement from the Task Force on Therapeutic Strategies of the ILAE Commission on Neuropsychobiology.Antiepileptic drug effects on mood and behavior: molecular targets.Emerging drugs for focal epilepsy.Investigating psychotropic properties of antiepileptic drugs.Epilepsy, behavior, and art (Epilepsy, Brain, and Mind, part 1).Epilepsy-induced behavioral changes during the ictal phase.Brivaracetam for the treatment of epilepsy in adults.The safety and tolerability of intranasal midazolam in epilepsy.Topiramate and cognitive impairment: evidence and clinical implications.More than seizures: improving the lives of people with refractory epilepsy.
P50
Q24648252-0571CBED-6874-4403-94FA-8C4BD0E6D426Q26743786-F7A56470-E06B-4064-9908-9E6012BA8D8CQ26743786-FEC3B2BE-2655-4F2F-BD78-07168FC0CDF2Q26865786-487ED664-E5C3-4A22-9F10-15C742CE77ECQ26995736-23E387F9-71E6-4062-8372-25C1C14FCC7CQ27013563-0ACDD158-A50F-4E0B-8E9F-F31E70D2CFC4Q28076687-D1FD3450-FC1C-4F74-B9D6-A2ACC7D8ABB5Q28559256-49875356-FB63-4298-9241-628E98C2C9BBQ28559256-5156B7C4-61F5-413D-A5C9-D67CF131D7A4Q30248909-D6B01367-6D08-4B00-B617-0FC03A038132Q33159637-75F80D82-435E-415F-8BDB-3BECE7E21FF2Q33467294-D117D9F0-CCAF-41F2-BAAE-CCE42C4FE8E6Q33956346-A29E1AC8-8C78-4771-B36E-B8B8519EF722Q34282867-24228FAF-1805-4517-88F7-3A9787A0C413Q34350056-AEEA809D-A8C5-4E73-B84D-6F3CBF64FAC8Q34580773-B9F8DE65-A55D-4461-A28F-512FE294997BQ34628014-9AE73893-F8AE-4B41-9095-ECFE9902EA16Q34628339-592976BB-5519-49C2-815C-E1496AF9298FQ34750940-B58C13C7-A8F2-48E8-B6F2-C2BB4388395FQ35065001-03702520-9B82-4C80-8466-F5548927A088Q36070297-B0A347B4-8041-4EC1-BD78-F0F059E9C3EDQ36070621-3BB98344-9BEC-40F1-9F15-360754A8D318Q36106896-1148B363-0343-4A63-BCDC-893B90B5EA8FQ36208326-13CA1D8F-C73C-4D9F-A126-453CC1B649E8Q36602127-13562140-8A95-4419-A9A3-BF86FEA7F460Q37114359-B44740CA-F83A-45C1-BF52-10146E741A78Q37242260-319A18D7-115C-479E-9136-564030AE5075Q37405700-D917B6B8-0CD2-41F3-A251-1CC5AE605592Q37658892-12B61572-C920-4D0D-B755-C1ADE332ABD5Q37754086-8F1FB84E-1A73-4D34-B09F-C54B22934D29Q37856281-C0BBEBA3-E9AF-432F-8270-D5DFFD784C79Q38014887-F7F1B896-B61D-493D-A87E-7227A9F22B83Q38045012-F41DB4EB-724D-4718-9EBD-6F0B00FE7A69Q38054948-3F6C6B36-5014-430F-A5C6-DAFBE7770117Q38062011-B09359CC-2337-4413-8116-AEB39C25D7BBQ38112212-F337C570-6347-4E69-9470-A386CC80B84CQ38114262-F634A3B0-2E28-4947-A035-DFE5F4C8DFD4Q38149462-C043CAB3-80D5-4CB7-85A4-135A26D95842Q38195636-4C373A69-0EE7-4B59-A143-7E7376542FF1Q38218631-0DAD3C00-53F1-41AC-B8C3-8F3BBA7692A9
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Marco Mula
@ast
Marco Mula
@en
Marco Mula
@es
Marco Mula
@nl
Marco Mula
@sl
type
label
Marco Mula
@ast
Marco Mula
@en
Marco Mula
@es
Marco Mula
@nl
Marco Mula
@sl
prefLabel
Marco Mula
@ast
Marco Mula
@en
Marco Mula
@es
Marco Mula
@nl
Marco Mula
@sl
P106
P1153
6603599916
P21
P2798
P31
P496
0000-0002-9415-3395